• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《2022年乳腺癌最新进展 第3部分 - 早期乳腺癌》

Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer.

作者信息

Fehm Tanja N, Welslau Manfred, Müller Volkmar, Lüftner Diana, Schütz Florian, Fasching Peter A, Janni Wolfgang, Thomssen Christoph, Witzel Isabell, Belleville Erik, Untch Michael, Thill Marc, Tesch Hans, Ditsch Nina, Lux Michael P, Aktas Bahriye, Banys-Paluchowski Maggie, Schneeweiss Andreas, Kolberg-Liedtke Cornelia, Hartkopf Andreas D, Wöckel Achim, Kolberg Hans-Christian, Harbeck Nadia, Stickeler Elmar

机构信息

Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.

Onkologie Aschaffenburg, Aschaffenburg, Germany.

出版信息

Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):912-921. doi: 10.1055/a-1912-7105. eCollection 2022 Sep.

DOI:10.1055/a-1912-7105
PMID:36110894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9470293/
Abstract

This review summarizes recent developments in the prevention and treatment of patients with early-stage breast cancer. The individual disease risk for different molecular subtypes was investigated in a large epidemiological study. With regard to treatment, new data are available from long-term follow-up of the Aphinity study, as well as new data on neoadjuvant therapy with atezolizumab in HER2-positive patients. Biomarkers, such as residual cancer burden, were investigated in the context of pembrolizumab therapy. A Genomic Grade Index study in elderly patients is one of a group of studies investigating the use of modern multigene tests to identify patients with an excellent prognosis in whom chemotherapy may be avoided. These and other aspects of the latest developments in the diagnosis and treatment of breast cancer are described in this review.

摘要

本综述总结了早期乳腺癌患者预防和治疗方面的最新进展。一项大型流行病学研究调查了不同分子亚型的个体疾病风险。在治疗方面，可获得Aphinity研究长期随访的新数据，以及关于阿替利珠单抗用于HER2阳性患者新辅助治疗的新数据。在帕博利珠单抗治疗的背景下对残余癌负荷等生物标志物进行了研究。一项针对老年患者的基因组分级指数研究是一组研究中的一项，这些研究旨在探索使用现代多基因检测来识别预后良好、可能无需化疗的患者。本综述描述了乳腺癌诊断和治疗最新进展的这些及其他方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/9b52322d9b16/10-1055-a-1912-7105-igfde04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/e3de08752b0d/10-1055-a-1912-7105-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/a7c1b118d13d/10-1055-a-1912-7105-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/67ef2dfa35c0/10-1055-a-1912-7105-igf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/4281158d8926/10-1055-a-1912-7105-igf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/fe79fd94e4bf/10-1055-a-1912-7105-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/a7c1b118d13d/10-1055-a-1912-7105-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/13a5ddf772c2/10-1055-a-1912-7105-igfde03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/9b52322d9b16/10-1055-a-1912-7105-igfde04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/e3de08752b0d/10-1055-a-1912-7105-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/a7c1b118d13d/10-1055-a-1912-7105-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/67ef2dfa35c0/10-1055-a-1912-7105-igf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/4281158d8926/10-1055-a-1912-7105-igf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/fe79fd94e4bf/10-1055-a-1912-7105-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/a7c1b118d13d/10-1055-a-1912-7105-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/13a5ddf772c2/10-1055-a-1912-7105-igfde03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a5e/9470293/9b52322d9b16/10-1055-a-1912-7105-igfde04.jpg

相似文献

1
Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer.《2022年乳腺癌最新进展 第3部分 - 早期乳腺癌》
Geburtshilfe Frauenheilkd. 2022 Sep 13;82(9):912-921. doi: 10.1055/a-1912-7105. eCollection 2022 Sep.
2
Update Breast Cancer 2022 Part 5 - Early Stage Breast Cancer.《2022年乳腺癌最新进展》第5部分 - 早期乳腺癌
Geburtshilfe Frauenheilkd. 2023 Mar 9;83(3):289-298. doi: 10.1055/a-2018-9053. eCollection 2023 Mar.
3
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者新辅助化疗后残余增殖性癌症负担预测长期结局的验证。
Oncologist. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21.
4
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.帕博利珠单抗联合新辅助化疗对早期乳腺癌患者病理完全缓解的影响：正在进行的 2 期适应性随机 I-SPY2 试验分析。
JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650.
5
Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.《2019年乳腺癌最新进展 第4部分 - 早期乳腺癌患者新型个性化治疗的诊断与治疗挑战》
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
6
Update Breast Cancer 2023 Part 1 - Early Stage Breast Cancer.《2023年乳腺癌最新进展 第1部分 - 早期乳腺癌》
Geburtshilfe Frauenheilkd. 2023 Jun 6;83(6):653-663. doi: 10.1055/a-2074-0551. eCollection 2023 Jun.
7
Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies.《2020年乳腺癌最新进展 第1部分 - 早期乳腺癌：已知疗法知识的整合》
Geburtshilfe Frauenheilkd. 2020 Mar;80(3):277-287. doi: 10.1055/a-1111-2431. Epub 2020 Mar 4.
8
Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.绝经后激素受体阳性早期乳腺癌患者的新辅助内分泌治疗：新概念。
Breast Cancer. 2011 Apr;18(2):92-7. doi: 10.1007/s12282-010-0233-6. Epub 2010 Dec 8.
9
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.早期乳腺癌辅助内分泌和化疗的生物标志物：ASCO 指南更新。
J Clin Oncol. 2022 Jun 1;40(16):1816-1837. doi: 10.1200/JCO.22.00069. Epub 2022 Apr 19.
10
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.阿替利珠单抗联合新辅助抗人表皮生长因子受体 2 治疗与化疗用于人表皮生长因子受体 2 阳性早期乳腺癌：随机 III 期 IMpassion050 试验的主要结果。
J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28.

引用本文的文献

1
A content-based review of mobile health applications for breast cancer prevention and education: Characteristics, quality and functionality analysis.基于内容的乳腺癌预防与教育移动健康应用综述：特征、质量与功能分析
Digit Health. 2024 Mar 15;10:20552076241234627. doi: 10.1177/20552076241234627. eCollection 2024 Jan-Dec.

本文引用的文献

1
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.AGO早期乳腺癌患者诊断与治疗建议：2022年更新版
Breast Care (Basel). 2022 Aug;17(4):403-420. doi: 10.1159/000524879. Epub 2022 May 5.
2
Ki67 as a Companion Diagnostic: Good or Bad News?Ki67作为伴随诊断指标：是好消息还是坏消息？
J Clin Oncol. 2022 Nov 20;40(33):3796-3799. doi: 10.1200/JCO.22.00581. Epub 2022 Jul 11.
3
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
阿替利珠单抗联合新辅助抗人表皮生长因子受体 2 治疗与化疗用于人表皮生长因子受体 2 阳性早期乳腺癌：随机 III 期 IMpassion050 试验的主要结果。
J Clin Oncol. 2022 Sep 1;40(25):2946-2956. doi: 10.1200/JCO.21.02772. Epub 2022 Jun 28.
4
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies.内在型乳腺癌亚型的独特生殖风险特征：基于人群的研究的汇总分析。
J Natl Cancer Inst. 2022 Dec 8;114(12):1706-1719. doi: 10.1093/jnci/djac117.
5
Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.绝经后妇女血浆中激素和核因子-κB（NF-κB）受体激活物（RANK）通路基因表达与乳腺 X 线摄影密度的关系。
Breast Cancer Res. 2022 Apr 14;24(1):28. doi: 10.1186/s13058-022-01522-2.
6
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
7
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.与 9 个乳腺癌易感基因中的致病性种系变异相关的肿瘤病理学。
JAMA Oncol. 2022 Mar 1;8(3):e216744. doi: 10.1001/jamaoncol.2021.6744. Epub 2022 Mar 17.
8
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?是否应采用Ki-67来选择接受辅助性阿贝西利治疗的乳腺癌患者？
Ann Oncol. 2022 Mar;33(3):234-238. doi: 10.1016/j.annonc.2021.12.004. Epub 2021 Dec 20.
9
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.21 基因检测在淋巴结阳性乳腺癌中预测化疗获益。
N Engl J Med. 2021 Dec 16;385(25):2336-2347. doi: 10.1056/NEJMoa2108873. Epub 2021 Dec 1.
10
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.辅助阿贝西利联合内分泌治疗高危早期乳腺癌： monarchE 研究的更新疗效和 Ki-67 分析。
Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14.